The conversion of apoB100 low density lipoprotein/high density lipoprotein particles to apoB100 very low density lipoproteins in response to oleic acid occurs in the endoplasmic reticulum and not in the Golgi in McA RH7777 cells - PubMed (original) (raw)
. 2003 Oct 24;278(43):42643-51.
doi: 10.1074/jbc.M306920200. Epub 2003 Aug 12.
Affiliations
- PMID: 12917397
- DOI: 10.1074/jbc.M306920200
Free article
The conversion of apoB100 low density lipoprotein/high density lipoprotein particles to apoB100 very low density lipoproteins in response to oleic acid occurs in the endoplasmic reticulum and not in the Golgi in McA RH7777 cells
Junji Yamaguchi et al. J Biol Chem. 2003.
Free article
Abstract
The site where bulk lipid is added to apoB100 low density lipoproteins (LDL)/high density lipoproteins (HDL) particles to form triglyceride-enriched very low density lipoproteins (VLDL) has not been identified definitively. We employed several strategies to address this question. First, McA RH7777 cells were pulse-labeled for 20 min with [35S]methionine/cysteine and chased for 1 h (Chase I) to allow study of newly synthesized apoB100 LDL/HDL remaining in the endoplasmic reticulum (ER). After Chase I, cells were incubated for another hour (C2) with/without brefeldin A (BFA) and nocodazole (Noc) (to block ER to Golgi trafficking) and with/without oleic acid (OA). OA treatment alone during C2 increased VLDL secretion. This was prevented by the addition of BFA/Noc in C2. When C2 media were replaced by control media for another 1-h chase (C3), VLDL formed during OA treatment in C2 were secreted into C3 medium. Thus, OA-induced conversion of apoB100 LDL/HDL to VLDL during C2 occurred in the ER. Next, newly synthesized apoB100 lipoproteins were trapped in the Golgi by treatment with Noc and monensin during Chase I (C1), and C2 was carried out in the presence of BFA/Noc with/without OA and without monensin. Under these conditions, OA treatment during C2 did not stimulate VLDL secretion. The same pulse/chase protocols were followed by iodixanol subcellular fractionation, extraction of lipoproteins from ER and Golgi, and sucrose gradient separation of extracted lipoproteins. Cells treated with BFA/Noc and OA in C2 had VLDL in the ER. In the absence of OA, only LDL/HDL were present in the ER. The density of Golgi lipoproteins in these cells was not affected by OA. Similar results were obtained when ER were immuno-isolated with anti-calnexin antibodies. In conclusion, apoB100 bulk lipidation, resulting in conversion of LDL/HDL to VLDL, can occur in the ER, but not in the Golgi, in McA RH7777 cells.
Similar articles
- Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells.
Tran K, Thorne-Tjomsland G, DeLong CJ, Cui Z, Shan J, Burton L, Jamieson JC, Yao Z. Tran K, et al. J Biol Chem. 2002 Aug 23;277(34):31187-200. doi: 10.1074/jbc.M200249200. Epub 2002 Jun 13. J Biol Chem. 2002. PMID: 12065576 - Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER.
Gusarova V, Brodsky JL, Fisher EA. Gusarova V, et al. J Biol Chem. 2003 Nov 28;278(48):48051-8. doi: 10.1074/jbc.M306898200. Epub 2003 Sep 5. J Biol Chem. 2003. PMID: 12960170 - Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells.
Borén J, Rustaeus S, Olofsson SO. Borén J, et al. J Biol Chem. 1994 Oct 14;269(41):25879-88. J Biol Chem. 1994. PMID: 7929292 - Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.
Olofsson SO, Borèn J. Olofsson SO, et al. J Intern Med. 2005 Nov;258(5):395-410. doi: 10.1111/j.1365-2796.2005.01556.x. J Intern Med. 2005. PMID: 16238675 Review. - Vesicular trafficking of hepatic apolipoprotein B100 and its maturation to very low-density lipoprotein particles; studies from cells and cell-free systems.
Brodsky JL, Gusarova V, Fisher EA. Brodsky JL, et al. Trends Cardiovasc Med. 2004 May;14(4):127-32. doi: 10.1016/j.tcm.2004.01.004. Trends Cardiovasc Med. 2004. PMID: 15177262 Review.
Cited by
- Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) stimulates VLDL assembly through activation of cell death-inducing DFFA-like effector B (CideB).
Chen Z, Norris JY, Finck BN. Chen Z, et al. J Biol Chem. 2010 Aug 20;285(34):25996-6004. doi: 10.1074/jbc.M110.141598. Epub 2010 Jun 15. J Biol Chem. 2010. PMID: 20551328 Free PMC article. - ApoA-IV modulates the secretory trafficking of apoB and the size of triglyceride-rich lipoproteins.
Weinberg RB, Gallagher JW, Fabritius MA, Shelness GS. Weinberg RB, et al. J Lipid Res. 2012 Apr;53(4):736-43. doi: 10.1194/jlr.M019992. Epub 2012 Jan 18. J Lipid Res. 2012. PMID: 22257482 Free PMC article. - Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets.
Chen J, Fang Z, Luo Q, Wang X, Warda M, Das A, Oldoni F, Luo F. Chen J, et al. Lipids Health Dis. 2024 Jan 12;23(1):14. doi: 10.1186/s12944-023-01993-y. Lipids Health Dis. 2024. PMID: 38216994 Free PMC article. - Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.
Choi SH, Ginsberg HN. Choi SH, et al. Trends Endocrinol Metab. 2011 Sep;22(9):353-63. doi: 10.1016/j.tem.2011.04.007. Epub 2011 May 26. Trends Endocrinol Metab. 2011. PMID: 21616678 Free PMC article. Review. - "Trans-nonachlor increases extracellular free fatty acid accumulation and de novo lipogenesis to produce hepatic steatosis in McArdle-RH7777 cells".
Howell GE 3rd, McDevitt E, Henein L, Mulligan C, Young D. Howell GE 3rd, et al. Toxicol In Vitro. 2018 Aug;50:285-292. doi: 10.1016/j.tiv.2018.04.003. Epub 2018 Apr 11. Toxicol In Vitro. 2018. PMID: 29654899 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous